Ovarian Suppression: Early Menopause, Late Effects

Curr Oncol Rep. 2024 May;26(5):427-438. doi: 10.1007/s11912-023-01491-5. Epub 2024 Jan 2.

Abstract

Purpose of review: Pre-menopausal women diagnosed with hormone receptor (HR) breast cancer are candidates for prolonged hypoestrogenism to improve cancer outcomes. However, the disease benefit eclipses the toxicities associated with ovarian function suppression (OFS), which are often under-reported.

Recent findings: Increased risk of mortality from cardiovascular disease, bone disorders, and metabolic disorders is well reported in women with no history of cancer, after surgical oophorectomy or premature ovarian failure. Vasomotor symptoms, urogenital atrophy, weight gain, sexual dysfunction, cognitive decline, and sleep disturbances contribute to the increased non-compliance associated with OFS, especially in younger women. Balancing the toxicities of prolonged OFS with its benefits should be critically analyzed by providers when making recommendations for their patients. Supportive care to manage multi-system toxicities and to counteract the long-term impact on all-cause mortality should be emphasized by every cancer program. Future studies with OFS should incorporate patient outcomes and strategies for symptom management in addition to focusing on improving disease outcomes.

Keywords: Breast cancer; Hormone receptor positive; Hypoestrogenism; Ovarian function suppression; Pre-menopausal.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms* / complications
  • Breast Neoplasms* / therapy
  • Cardiovascular Diseases / etiology
  • Female
  • Humans
  • Menopause, Premature*
  • Ovariectomy / adverse effects
  • Ovary
  • Primary Ovarian Insufficiency / etiology
  • Primary Ovarian Insufficiency / therapy